Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

QRxPharma Ltd.

www.qrxpharma.com

Latest From QRxPharma Ltd.

Turning the Page on Zohydro? New Formulations, New Division Leadership Should Help FDA Move Forward in Opioids

The long-time head of FDA’s pain drug review group, Bob Rappaport, has retired after 20 years at FDA. The new acting Division Director is Sharon Hertz – suggesting continuity in the substance of reviews, but perhaps a symbolic change in moving beyond the controversy over Zohydro.

Turning the Page on Zohydro? New Formulations, New Division Leadership Should Help FDA Move Forward in Opioids

The long-time head of FDA’s pain drug review group, Bob Rappaport, has retired after 20 years at FDA. The new acting Division Director is Sharon Hertz – suggesting continuity in the substance of reviews, but perhaps a symbolic change in moving beyond the controversy over Zohydro.

BioPharmaceutical Regulation

Execs On The Move, July-August 2014

Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.

BioPharmaceutical Medical Device

REJECTED: Strike 3 for QRxPharma's opioids combo MoxDuo

The FDA for the third time has rejected QRxPharma's application for its morphine/oxycodone combination drug MoxDuo – news that sent shares of the firm tumbling as low as 15.4% on 27 May.

Neurology Respiratory
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • QRxPharma Pty. Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Australia
  • Parent & Subsidiaries
  • QRxPharma Ltd.
  • Senior Management
  • Edward Rudnic, PhD, CEO
    Chris J Campbell, CFO
    Janette Dixon, PhD, SVP, Bus. Dev.
  • Contact Info
  • QRxPharma Ltd.
    Phone: (61) (2) 8404 4139
    100 Walker St.
    Level 11,Ste. 1
    North Sydney, 2060
    Australia
UsernamePublicRestriction

Register